Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women

JAMA

Volumn 285, Issue 11, 2001, Pages 1460-1465

  Rodriguez, C ^a   Patel, A V ^a   Calle, E E ^a   Jacob, E J ^a   Thun, M J ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; DEMOGRAPHY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

EID: 0035925788     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.11.1460     Document Type: Article

References (43)

1. Association of exogenous estrogen and endometrial carcinoma
2. Increased risk of endometrial carcinoma among users of conjugated estrogens
3. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
4. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies, IV: The pathogenesis of epithelial ovarian cancer
5. Determinants of ovarian cancer risk, I: Reproductive experiences and family history
6. Determinants of ovarian cancer risk, II: Inferences regarding pathogenesis
7. Menopause and ovarian cancer
8. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results from a casecontrol study
9. Stilbestrol (diethylstilbestrol) and the risk of ovarian cancer
10. Ovarian cancer: Incidence and casecontrol study
11. An epidemiologic study of epithelial carcinoma of the ovary
12. Noncontraceptive estrogen use and the occurence of ovarian cancer
13. Case-control study of borderline ovarian tumors: Reproductive history and exposure to exogenous female hormones
14. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 U S case-control studies, III: Epithelial tumors of low malignant potential in white women
15. Risk factors for ovarian cancer: A case-control study
16. Noncontraceptive estrogen use and the occurrence of ovarian cancer
17. The epidemiology of ovarian cancer in Greece: A case-control study
18. Estrogen therapy and the risk of breast, ovarian, and endometrial cancer
19. Noncontraceptive estrogen use and epithelial ovarian cancer
20. Reproductive variables, tobacco, ethanol, coffee, and somatometry as risk factors for ovarian cancer
21. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies
22. Hormone replacement therapy and risk of epithelial ovarian cancer
23. Estrogen replacement therapy and ovarian cancer risk
24. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies, II: Invasive epithelial ovarian cancers in white women
25. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis
26. Estrogen replacement therapy and risk of epithelial ovarian cancer
27. Estrogen replacement therapy and fatal ovarian cancer
28. Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women
29. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA
30. Serum FSH, LH, and oestrone levels in postmenopausal patients on oestrogen therapy
31. Serum gonadotropins and steroid hormones and the development of ovarian cancer
32. Cancer of the ovary
33. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells
34. Tamoxifen in platinumrefractory ovarian cancer: A Gynecologic Oncology Group ancillary report
35. Noncontraceptive estrogens and progestins: Use patterns over time
36. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992
37. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
38. Hormonal etiology of epithelial ovarian cancer, with a hypothesis considering the role of androgens and progesterone
39. Relative risks and benefits of long-term estrogen replacement therapy: A decision analysis
40. Hormone replacement therapy
41. Hormone-replacement therapy breast versus heart versus bone